Spyre Therapeutics (SYRE) Other financing activities (2017 - 2026)

Spyre Therapeutics' Other financing activities history runs 10 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• Quarterly Other financing activities rose 1127.52% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (up 158.93% YoY) and the FY2024 annual result came in at $1000.0, down 99.75% from the prior year.
• Other financing activities was $2.7 million for Q1 2026 at Spyre Therapeutics, up from -$1.6 million in the prior quarter.
• Across five years, Other financing activities topped out at $164.7 million in Q2 2024 and bottomed at -$162.9 million in Q3 2024.
• A 5-year average of $236000.0 and a median of $201000.0 in 2022 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 24288.89% in 2024, while the deepest fall reached 155211.43% in 2024.
• Spyre Therapeutics' Other financing activities stood at $38000.0 in 2022, then jumped by 642.11% to $282000.0 in 2023, then slumped by 2299.29% to -$6.2 million in 2024, then jumped by 74.9% to -$1.6 million in 2025, then surged by 271.87% to $2.7 million in 2026.
• Business Quant data shows SYRE's Other financing activities at $2.7 million in Q1 2026, -$1.6 million in Q4 2025, and $491000.0 in Q3 2025.